What Researchers Did
Researchers reported on two patients in Peru with COVID-19-associated mucormycosis who received adjunctive hyperbaric oxygen therapy after initial treatment failed.
What They Found
Both patients, a 41-year-old woman and a 35-year-old man, had COVID-19-associated mucormycosis and initially showed poor progression despite debridement and amphotericin B. After adding hyperbaric oxygen therapy, both patients demonstrated evident improvement within four weeks, with subsequent controls showing no presence of mucormycosis.
What This Means for Canadian Patients
For Canadian patients with severe COVID-19-associated mucormycosis who do not respond to standard treatments, adjunctive hyperbaric oxygen therapy might be considered as a potential treatment option. This approach could offer an alternative strategy to improve outcomes in a disease with high morbidity and mortality.
Canadian Relevance
This study has no direct Canadian connection as it reports on cases from Peru.
Study Limitations
A significant limitation of this study is its design as a case report, which prevents generalization of findings due to the small sample size and lack of a control group.